AACE/ACE DIABETES ALGO LIFESTYLE M
Excerpted from: Rodbard HW, Jellinger PS, Davidson JA, et al. American Association of on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 1
A1C 6.5-7.5%** Monotherapy
MET† DPP41 GLP-1 TZD2 Dual Therapy MET +
GLP-1 or DPP41 TZD2
Glinide or SU5 TZD + GLP-1 or DPP41
MET + Colesevelam AGI3
2-3 Mos.***
MET + GLP-1 or DPP41
Triple Therapy + TZD2
Glinide or SU4,7 2-3 Mos.*** INSULIN ± Other Agent(s)6 AGI3 2-3 Mos.***
A1C 7.6-9.0% Dual Therapy8
MET + GLP-1 or DPP41 SU or Glinide4,5
Triple Therapy9 GLP-1 or DPP41
MET + GLP-1 or DPP41 TZD2
+ TZD2 + SU7
2-3 Mos.*** INSULIN ± Other Agent(s)6 or TZD2 2-3 Mos.***
Cochairpersons: Helena W. Rodbard, MD, FACP, MACE Paul S. Jellinger, MD, MACE
Zachary T. Bloomgarden, MD, FACE Jaime A. Davidson, MD, FACP, MACE Daniel Einhorn, MD, FACP, FACE Alan J. Garber, MD, PhD, FACE James R. Gavin III, MD, PhD George Grunberger, MD, FACP, FACE
AACE/ACE Algorithm for Glycemic Control Subcommittee
Yehuda Handelsman, MD, FACP, FACE Edward S. Horton, MD, FACE Harold Lebovitz, MD, FACE Philip Levy, MD, MACE Etie S. Moghissi, MD, FACP, FACE Stanley S. Schwartz, MD, FACE
